Dimensional Fund Advisors LP Trims Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Dimensional Fund Advisors LP decreased its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 31.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,062 shares of the biotechnology company’s stock after selling 60,194 shares during the quarter. Dimensional Fund Advisors LP owned 0.61% of Enanta Pharmaceuticals worth $1,674,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at approximately $35,000. State Board of Administration of Florida Retirement System purchased a new stake in Enanta Pharmaceuticals during the first quarter valued at approximately $118,000. Quest Partners LLC increased its holdings in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares during the last quarter. Virtu Financial LLC purchased a new stake in Enanta Pharmaceuticals during the first quarter valued at approximately $191,000. Finally, American Century Companies Inc. increased its holdings in Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 7,287 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA opened at $11.04 on Friday. The firm has a fifty day moving average price of $11.98 and a 200-day moving average price of $13.24. The stock has a market cap of $233.94 million, a PE ratio of -2.03 and a beta of 0.58. Enanta Pharmaceuticals, Inc. has a 1 year low of $8.08 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.36. The firm had revenue of $17.97 million during the quarter, compared to analysts’ expectations of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.27) earnings per share. On average, research analysts expect that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current year.

Insider Buying and Selling

In related news, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now owns 21,717 shares in the company, valued at approximately $370,926.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.64% of the stock is owned by company insiders.

Analysts Set New Price Targets

ENTA has been the subject of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.